A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society(2016)
摘要
BACKGROUND:Cystic fibrosis (CF) patients experience intestinal complications characterized by the accumulation of thick viscous mucus. CF mice were utilized to determine if a novel guluronate oligomer, OligoG, may be a potential therapy in reducing intestinal mucus and subsequent CF-related intestinal manifestations.
METHODS:Intestinal transit, intestinal histology, survival and growth were examined in wildtype and CF mice on regular water and OligoG.
CONCLUSIONS:OligoG improves intestinal transit and survival in CF mice by reducing the accumulation of intestinal mucus. OligoG's ability to directly bind mucin, disrupt mucin interaction and/or sequester calcium allowing for mucin expansion may explain the decrease in mucus accumulation.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要